Levodopa/Carbidopa/Entacapon Al

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone, is a combination drug presented as a tablet for oral use. It treats Parkinson's disease and associated motor fluctuations in adult patients. GNH USA supplies Levodopa/Carbidopa/Entacapone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinsonian disorders and related motor complications. - Parkinson's disease: improves overall motor function and reduces rigidity. - Parkinson's disease motor fluctuations: decreases "OFF" periods and prolongs "ON" time. - Early Parkinsonian symptoms: helps control tremor and bradykinesia in newly diagnosed patients.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic blood pressure changes. - Headache: transient and usually resolves with continued therapy. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that may be disabling. - Hallucinations: visual or auditory disturbances, especially in older patients. - Severe hypotension: marked drop in blood pressure leading to fainting or falls.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; liver disease may alter drug metabolism. - Cardiovascular disease: observe for orthostatic hypotension and arrhythmias. - Psychiatric history: patients with psychosis are at higher risk for hallucinations. - Concomitant MAO‑B inhibitors: avoid co‑administration due to potential hypertensive crisis. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several drug classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Anticholinergic agents: can mask Parkinsonian symptoms and reduce efficacy. - Serotonergic drugs (e.g., SSRIs, tramadol): increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure‑lowering effect. - Iron or calcium supplements: may decrease levodopa absorption if taken simultaneously. - High‑protein meals: compete for transport across the gut, potentially reducing drug bioavailability.